Survival and recurrence rates in Australians with HER2-positive early breast cancer are “reassuringly” comparable to those reported in landmark clinical trials despite only two-thirds of patients completing the standard 12-month course of trastuzumab (Herceptin), new real-world data reveals. The observational study of almost 15,000 HER2-positive early breast cancer patients who received adjuvant trastuzumab between 2007 ...
How real-world HER2+ early breast cancer patients differ from RCTs
By Mardi Chapman
10 Dec 2019